- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech High Return On Equity, Low Debt
Hong Kong Pharmaceuticals & Biotech High Return On Equity, Low Debt
Results
2
0 new
Stocks with a return on equity of over 30% and a debt to equity ratio below 1.
2 companies
RemeGen
Market Cap: HK$58.2b
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
9995
HK$68.40
7D
-1.2%
1Y
36.0%
Qyuns Therapeutics
Market Cap: HK$3.4b
A clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China.
2509
HK$15.20
7D
1.5%
1Y
5.8%